



第 347 回 つくば分子生命科学セミナー

TSUKUBA MOLECULAR LIFE SCIENCE SEMINAR

演題 : Advancement and challenges in molecular targeted therapy—from cells and mice to human

演者 : Dr. Chie Sakanaka
Genentech Inc.

日時 : 2012 年 3 月 28 日 (水) 17:00-18:30

会場 : 医学学群棟 4 階 4 1 1 室

要旨 :

Targeted cancer therapies are emerging as promising approaches for treating human cancer. Cancer cells are thought to activate specific signaling pathways or express specific proteins. Targeted therapy is anticipated to show low toxicity compared to conventional chemotherapeutic reagents, due to the highly selective tumor cell killing without affecting normal cells by molecular targeting. One of the active areas in protein-based targeted therapeutics is using monoclonal antibodies. I will discuss current advancements in tumor targeting using antibody technology, particularly antibody-drug conjugates (“armed” antibody), and also T-cell engaging bi-specific antibody. These strategies require tumor restricted cell surface antigen and target specific monoclonal antibody. I will overview how we select and validate the target molecules, evaluate monoclonal antibodies, and nominate therapeutic candidate. I would also like to discuss our research on mechanism of Wnt signaling inhibitors, and the importance of different types of cells co-existed in tumors using Wnt signaling driven mouse breast cancer model.

連絡先 : 人間総合科学研究科 大根田 修 (内線 2938)

【筑波分子医学協会 (TSM) 主催】 HP <http://www.md.tsukuba.ac.jp/public/tsm/>

TSM セミナー担当 筑波大学医学医療系 入江賢児